Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Incorrect dose administered? 174 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 174 reports of Incorrect dose administered have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.2% of all adverse event reports for TOCILIZUMAB.

174
Reports of Incorrect dose administered with TOCILIZUMAB
0.2%
of all TOCILIZUMAB reports
2
Deaths
33
Hospitalizations

How Dangerous Is Incorrect dose administered From TOCILIZUMAB?

Of the 174 reports, 2 (1.1%) resulted in death, 33 (19.0%) required hospitalization, and 1 (0.6%) were considered life-threatening.

Is Incorrect dose administered Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 174 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Incorrect dose administered?

TIRZEPATIDE (23,301) ADALIMUMAB (14,000) DUPILUMAB (9,907) RANITIDINE (9,337) INSULIN LISPRO (8,318) ACETAMINOPHEN (5,316) DULAGLUTIDE (5,207) SECUKINUMAB (4,524) INSULIN GLARGINE (3,070) SOMATROPIN (2,772)

Which TOCILIZUMAB Alternatives Have Lower Incorrect dose administered Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Incorrect dose administered Reports All Drugs Causing Incorrect dose administered TOCILIZUMAB Demographics